First Clinical Trial in MOGAD Meets Primary Endpoint
Summary
Satralizumab cuts relapse risk in myelin oligodendrocyte glycoprotein antibody-associated disease
Description
Satralizumab cuts relapse risk in myelin oligodendrocyte glycoprotein antibody-associated disease
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source